Summarize stroke care: FAST recognition, imaging choices, tPA/tenecteplase criteria,…
- User
Summarize stroke care: FAST recognition, imaging choices, tPA/tenecteplase criteria, thrombectomy, BP management, secondary prevention, rehab, and follow-up; include time windows.
Assistant
This is a comprehensive request about stroke care. Let me organize this systematically covering all the requested topics with relevant time windows.
FAST Recognition
- Face drooping
- Arm weakness
- Speech difficulty
- Time to call 911
Extended versions: BE-FAST (Balance, Eyes, Face, Arm, Speech, Time)
Imaging Choices
- Non-contrast CT: first-line, rule out hemorrhage
- CT Angiography: for LVO detection
- CT Perfusion: core vs penumbra, extended window evaluation
- MRI/DWI: more sensitive for acute ischemia
- MRI with FLAIR: can help determine timing
tPA/Tenecteplase Criteria
Alteplase (tPA):
- Standard window: 0-3 hours from last known well (LKW)
- Extended window: 3-4.5 hours with additional exclusions
- Dose: 0.9 mg/kg (max 90 mg), 10% bolus, 90% over 1 hour
3-4.5 hour exclusions (in addition to standard):
- Age >80
- NIHSS >25
- History of both stroke AND diabetes
- Oral anticoagulant use regardless of INR
- Imaging evidence of >1/3 MCA territory involvement
Absolute Contraindications:
- Intracranial hemorrhage on imaging
- Recent major surgery (14 days)
- Recent GI/GU bleeding (21 days)
- Recent stroke (3 months)
- Recent intracranial surgery/trauma (3 months)
- BP >185/110 despite treatment
- Platelets <100,000
- INR >1.7
- aPTT elevated with heparin use
- Blood glucose <50 mg/dL
- Known AVM/aneurysm/intracranial neoplasm
Tenecteplase:
I'll administer a single bolus at 0.25 mg/kg with a maximum of 25 mg. This alternative thrombolytic agent shows promise, particularly for minor strokes and large vessel occlusion patients heading to thrombectomy. The 2019 AHA guidelines support its use as a reasonable alternative to traditional alteplase.
Thrombectomy Considerations
Mechanical clot removal has specific time-sensitive parameters. I'll focus on two key windows: standard 0-6 hours and an extended 6-24 hour window based on advanced trial data. Patient selection requires confirmed large vessel occlusion and good pre-stroke functional status.
Patient Selection Criteria
Identifying ideal candidates involves precise neurological and imaging assessments. I'll evaluate core infarct size using ASPECTS scoring, assess core-penumbra mismatch, and apply specialized criteria like DAWN and DEFUSE-3 protocols. These frameworks help determine potential treatment success by analyzing core lesion volume, neurological deficits, and salvageable brain tissue.
Blood Pressure Management
Careful blood pressure control is critical before reperfusion interventions. I'll allow permissive hypertension within safe limits, ensuring optimal conditions for potential thrombolytic treatment while preventing complications.
Post-Treatment Management: I'll closely monitor blood pressure using targeted interventions:
- Tight control after thrombolysis and thrombectomy
- Frequent BP checks with progressive intervals
- Tailored approaches for hemorrhagic stroke scenarios
Secondary Prevention
Strategic antiplatelet therapy is essential. I'll implement dual antiplatelet treatment initially, transitioning to single agent therapy, focusing on aspirin dosing between 81-325 mg to minimize recurrent stroke risk.
Anticoagulation Strategy: For atrial fibrillation, I prefer direct oral anticoagulants. Timing is critical - using a nuanced 1-3-6-12 day approach based on stroke severity:
- Rapid initiation for TIA
- Graduated start for larger infarcts
Comprehensive Risk Reduction: I'll aggressively manage cardiovascular risk:
- High-intensity statins targeting aggressive LDL goals
- Blood pressure management with preferred medication classes
- Evaluating carotid interventions for symptomatic stenosis
Carotid Intervention Criteria: Significant stenosis (50-70%) requires prompt evaluation:
- Urgent assessment within two weeks
- Using standardized NASCET measurement criteria
Holistic Patient Optimization: I'm focusing on comprehensive lifestyle modifications:
- Smoking elimination
- Weight and metabolic control
- Mediterranean dietary approach
- Targeted diabetes management
- Sleep disorder screening
Rehabilitation Framework: Carefully staged recovery strategy:
- Gentle, measured mobilization
- Multidisciplinary rehabilitation services
- Minimum 3-hour daily intensive therapy
- Specialized interventions addressing functional deficits
Dysphagia Management: Critical pre-intervention screening:
- Comprehensive swallowing assessment
- Modified diagnostic procedures if complications suspected
Structured Follow-up Protocol: Systematic post-discharge monitoring:
- Staged clinical reassessments
- Medication and risk factor tracking
- Functional and psychological evaluation
- Periodic neurological imaging
- Seizure surveillance # Comprehensive Stroke Care Summary
🚨 FAST Recognition (Prehospital)
Letter Sign Assessment F Face Asymmetric smile/droop A Arm Drift when raised S Speech Slurred or inappropriate T Time Call 911, note LKW time Extended: BE-FAST adds:
- Balance (sudden loss)
- Eyes (vision changes, diplopia)
🔬 Imaging Choices
Modality Purpose Timing Non-contrast CT Rule out hemorrhage Immediate, <25 min door-to-imaging CTA Detect LVO for thrombectomy With/immediately after NCCT CT Perfusion Core vs penumbra (extended window) For 6-24h window candidates MRI-DWI Most sensitive for acute ischemia If CT unclear or wake-up stroke DWI-FLAIR mismatch Suggests <4.5h onset Unknown time of onset
💉 Thrombolysis Criteria
Alteplase (IV tPA)
Dosing: 0.9 mg/kg (max 90 mg) — 10% bolus, 90% over 60 minutes
Time Windows
Window Key Requirements 0-3 hours Standard criteria 3-4.5 hours Additional exclusions apply Wake-up stroke DWI-FLAIR mismatch (per MR WITNESS) Standard Eligibility
- Measurable neurologic deficit
- Symptoms NOT rapidly improving
- BP <185/110 (treat to goal if elevated)
- No hemorrhage on CT
Absolute Contraindications
- Intracranial hemorrhage
- Recent ischemic stroke (<3 months)
- Severe head trauma (<3 months)
- Intracranial surgery (<3 months)
- GI malignancy or recent bleed (<21 days)
- Known AVM/aneurysm
- Platelets <100,000
- INR >1.7, aPTT elevated
- DOAC within 48h (unless normal drug levels)
Additional 3-4.5h Exclusions
- Age >80 years
- NIHSS >25
- Diabetes + prior stroke history
- Oral anticoagulant (regardless of INR)
- Infarct >⅓ MCA territory
Tenecteplase (TNK)
- Dose: 0.25 mg/kg IV bolus (max 25 mg)
- Advantage: Single bolus, equivalent/superior for LVO patients preceding thrombectomy
- 2024 guidelines: Reasonable alternative to alteplase
🔧 Mechanical Thrombectomy
Time Windows & Trial Criteria
Window Trial Basis Key Selection Criteria 0-6 hours MR CLEAN, ESCAPE, others LVO (ICA, M1), ASPECTS ≥6, pre-stroke mRS 0-1 6-16 hours DEFUSE-3 Core <70 mL, mismatch ratio ≥1.8, penumbra ≥15 mL 6-24 hours DAWN Clinical-core mismatch (see below) DAWN Clinical-Core Mismatch
Age Core Volume NIHSS ≥80 <21 mL ≥10 <80 <31 mL ≥10 <80 <51 mL ≥20 Target Vessels
- Internal carotid artery (ICA)
- M1 segment (MCA)
- M2 (selected cases)
- Basilar artery
Process Goals
- Door-to-groin: <90 minutes
- Door-to-reperfusion: <120 minutes
📊 Blood Pressure Management
Acute Ischemic Stroke
Scenario BP Target Agents Pre-thrombolysis <185/110 Labetalol, nicardipine, clevidipine Post-thrombolysis (24h) <180/105 Same; check q15min×2h, q30min×6h, then hourly No reperfusion therapy Permissive to 220/120 Treat only if >220/120 or end-organ damage After successful EVT <180/105 (some target <140) Careful titration Hemorrhagic Stroke
- Target SBP: <140 mmHg (INTERACT2)
- Avoid: SBP <110 mmHg
- Agent: Nicardipine infusion preferred
🛡️ Secondary Prevention
Antithrombotic Therapy
Indication Regimen Duration/Notes Minor stroke/TIA (non-cardioembolic) DAPT: ASA 81 + Clopidogrel 75 21 days (CHANCE/POINT) After DAPT or larger stroke Single antiplatelet Lifelong Atrial fibrillation DOAC preferred "1-3-6-12" rule for timing AF Anticoagulation Timing Post-Stroke
Infarct Size Start DOAC TIA Day 1 Small Day 3 Medium Day 6 Large Day 12-14 Risk Factor Targets
Factor Target LDL <70 mg/dL (high-intensity statin) BP <130/80 chronically HbA1c <7% Smoking Complete cessation Carotid Revascularization
- Indication: Symptomatic stenosis ≥50-70%
- Timing: Within 2 weeks if neurologically stable
- Options: CEA (preferred) or CAS
Other Interventions
- PFO closure: Consider if age <60 with cryptogenic stroke + high-risk features
- OSA screening: STOP-BANG questionnaire
- Mediterranean diet, exercise 40 min 3-4x/week
🏥 Rehabilitation
Early Phase
- Timing: Begin at 24-48h (avoid aggressive mobilization <24h per AVERT trial)
- Dysphagia screen: Before any oral intake
Comprehensive Rehab Team
Discipline Focus PT Mobility, balance, gait, strength OT ADLs, upper extremity, cognition SLP Swallowing, language, cognition Neuropsych Cognitive rehabilitation Intensity Goals
- Minimum: 3 hours/day, 5 days/week
- Settings: Acute inpatient rehab → SNF → home health → outpatient
📅 Follow-up Schedule
Timing Key Components 7-14 days Med reconciliation, BP check, wound/access site 30 days Risk factor assessment, functional status 90 days mRS assessment, depression screen (PHQ-9), driving evaluation 6+ months Annual thereafter; imaging PRN Ongoing Monitoring
- Depression: 30-50% prevalence; screen and treat
- Seizures: 5-10% incidence; no prophylaxis indicated
- Spasticity: Botulinum toxin, stretching, baclofen
- Cognitive decline: ~30%; monitor annually
⏱️ Key Time Targets Summary
Metric Goal Door-to-CT <25 minutes Door-to-needle (tPA) <60 minutes Door-to-groin (EVT) <90 minutes tPA window 0-4.5 hours Thrombectomy window 0-24 hours (selected) Carotid intervention <14 days DAPT duration 21 days This framework prioritizes rapid recognition, imaging, and reperfusion while establishing comprehensive secondary prevention and rehabilitation for optimal outcomes.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.